Dr. James Wells
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 18
Licensed in Alabama since 2007, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Texas Medical School at Houston
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
AL license 27878 (first issued 2007; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 18
- Services billed
- 39
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 21 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Birmingham, AL | 53 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Birmingham, AL | 38 |
| Azithromycin Other prescribers in Birmingham, AL | 31 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Birmingham, AL | 21 |
| Prolastin C (alpha-1-proteinase inhibitor) | 20 |
| Montelukast Sodium Other prescribers in Birmingham, AL | 18 |
| Prednisone Other prescribers in Birmingham, AL | 15 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Birmingham, AL | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 17 payments worth $105,530 in total to this clinician.
| AstraZeneca UK Limited | $82,600 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $13,216 |
| Grifols Shared Services North America, Inc. | $6,888 |
| AstraZeneca Pharmaceuticals LP | $2,700 |
| Verona Pharma, Inc. | $112 |
| Stryker Corporation | $14.50 |
| Consulting Fee | $93,276 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $12,010 |
| Food and Beverage | $245 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Jul 31, 2025 | Consulting Fee BREZTRI · Respiratory | $21,500 |
| AstraZeneca UK Limited Nov 7, 2025 | Consulting Fee BREZTRI · Respiratory | $21,000 |
| AstraZeneca UK Limited Dec 4, 2025 | Consulting Fee BREZTRI · Respiratory | $14,600 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) GLASSIA · IMMUNOLOGY · in-kind | $12,010 |
| AstraZeneca UK Limited Jul 31, 2025 | Consulting Fee BREZTRI · Respiratory | $11,650 |
| AstraZeneca UK Limited May 8, 2025 | Consulting Fee BREZTRI · Respiratory | $10,600 |
| Grifols Shared Services North America, Inc. Mar 21, 2025 | Consulting Fee Prolastin-C Liquid · Pulmonology | $6,888 |
| AstraZeneca UK Limited Apr 3, 2025 | Consulting Fee BREZTRI · Respiratory | $3,250 |
| AstraZeneca Pharmaceuticals LP Apr 23, 2025 | Consulting Fee BREZTRI · Respiratory | $1,300 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 28, 2025 | Consulting Fee GLASSIA · IMMUNOLOGY | $1,188 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca UK Limited Dec 4, 2025 | Consulting Fee BREZTRI · Respiratory | $14,600 |
| AstraZeneca UK Limited Nov 7, 2025 | Consulting Fee BREZTRI · Respiratory | $21,000 |
| AstraZeneca UK Limited Jul 31, 2025 | Consulting Fee BREZTRI · Respiratory | $21,500 |
| AstraZeneca UK Limited Jul 31, 2025 | Consulting Fee BREZTRI · Respiratory | $11,650 |
| AstraZeneca Pharmaceuticals LP May 22, 2025 | Consulting Fee BREZTRI · Respiratory | $400 |
| AstraZeneca UK Limited May 8, 2025 | Consulting Fee BREZTRI · Respiratory | $10,600 |
| AstraZeneca Pharmaceuticals LP Apr 23, 2025 | Consulting Fee BREZTRI · Respiratory | $1,300 |
| AstraZeneca UK Limited Apr 3, 2025 | Consulting Fee BREZTRI · Respiratory | $3,250 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) GLASSIA · IMMUNOLOGY · in-kind | $12,010 |
| Grifols Shared Services North America, Inc. Mar 21, 2025 | Consulting Fee Prolastin-C Liquid · Pulmonology | $6,888 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 28, 2025 | Consulting Fee GLASSIA · IMMUNOLOGY | $1,188 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Consulting Fee TEZSPIRE · Respiratory | $900 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $267,434 in research payments for these studies, mostly to the institutions running them.
- Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Verona Pharma, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.